Early studies on iORFV demonstrated anti‐tumour effects against mouse malignant melanoma and human breast cancer cells, in which NK cells and cytokines (IFN‐γ and IL‐12) play important roles [57]. This evidence concerns the gene IFNG and breast carcinoma.